| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11395856 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
| US10022460 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583207 | LANTHEUS MEDCL | Lipid-encapsulated gas microsphere compositions and related methods |
Dec, 2035
(11 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11857646 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US11925695 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(13 years from now) | |
Definity Rt is owned by Lantheus Medcl.
Definity Rt contains Perflutren.
Definity Rt has a total of 10 drug patents out of which 0 drug patents have expired.
Definity Rt was authorised for market use on 31 July, 2001.
Definity Rt is available in injectable;intravenous dosage forms.
Definity Rt can be used as method of using the drug substance/drug product for ultrasound imaging.
The generics of Definity Rt are possible to be released after 04 May, 2037.
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
DEFINITY RT family patents
